Literature DB >> 6214342

Defect in the generation of cytotoxic T cells in lepromatous leprosy.

J L Stach, M Strobel, F Fumoux, J F Bach.   

Abstract

Cytotoxic T cells are consistently produced in normal individuals after in vitro stimulation by a pool of mitomycin-treated normal lymphocytes. Patients suffering from lepromatous leprosy (LL), presenting with large amounts of Mycobacterium leprae and without a history of erythema nodosum leprosum (ENL) are unable to generate such cytotoxic T cells, while lepromatous patients with ENL which, in the present study were all deprived of M. leprae, react normally.

Entities:  

Mesh:

Year:  1982        PMID: 6214342      PMCID: PMC1536602     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  Immunologic reactivity in patients with leprosy.

Authors:  J N Sheagren; J B Block; J R Trautman; S M Wolff
Journal:  Ann Intern Med       Date:  1969-02       Impact factor: 25.391

2.  Prolonged survival of skin allografts in leprosy patients.

Authors:  S H Han; R S Weiser; S T Kau
Journal:  Int J Lepr Other Mycobact Dis       Date:  1971 Jan-Mar

3.  Production of macrophage inhibitory factor by patients with leprosy.

Authors:  S I Katz; B H DeBetz; N Zaias
Journal:  Arch Dermatol       Date:  1971-04

4.  Significance of variations within the lepromatous group.

Authors:  D S Ridley; M F Waters
Journal:  Lepr Rev       Date:  1969-07       Impact factor: 0.537

5.  Immunologic suppression in leprosy and its relation to lepromatous disease.

Authors:  C C Shepard
Journal:  Int J Lepr Other Mycobact Dis       Date:  1968 Jan-Mar

6.  Phytohaemagglutinin-induced lymphocyte transformation in leprosy.

Authors:  D S Nelson; M Nelson; J M Thurston; M F Waters; J M Pearson
Journal:  Clin Exp Immunol       Date:  1971-07       Impact factor: 4.330

7.  [Study ofn leprosy immunity].

Authors:  M Salazar Mallén; A Chévez Zamora; J Montes Montes; A Escobar; D Mitrani Levy; M E Amezcua
Journal:  Alergia       Date:  1971-05

8.  Studies on T cell subsets and functions in leprosy.

Authors:  M A Bach; L Chatenoud; D Wallach; F Phan Dinh Tuy; F Cottenot
Journal:  Clin Exp Immunol       Date:  1981-06       Impact factor: 4.330

9.  Studies of immune mechanisms in leprosy. 3. The role of cellular and humoral factors in impairment of the in vitro immune response.

Authors:  W E Bullock; P Fasal
Journal:  J Immunol       Date:  1971-04       Impact factor: 5.422

10.  Classification of leprosy according to immunity. A five-group system.

Authors:  D S Ridley; W H Jopling
Journal:  Int J Lepr Other Mycobact Dis       Date:  1966 Jul-Sep
View more
  6 in total

Review 1.  T cell and cytokine patterns in leprosy skin lesions.

Authors:  P A Sieling; R L Modlin
Journal:  Springer Semin Immunopathol       Date:  1992

2.  Epidermal keratinocyte Ia expression, Langerhans cell hyperplasia and lymphocytic infiltration in skin lesions of leprosy.

Authors:  T H Rea; J Y Shen; R L Modlin
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

3.  In situ characterization of T lymphocyte subsets in the reactional states of leprosy.

Authors:  R L Modlin; J F Gebhard; C R Taylor; T H Rea
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

4.  Expression of adhesion molecules in leprosy lesions.

Authors:  L Sullivan; S Sano; C Pirmez; P Salgame; C Mueller; F Hofman; K Uyemura; T H Rea; B R Bloom; R L Modlin
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

5.  Tumor necrosis factor production in patients with leprosy.

Authors:  P F Barnes; D Chatterjee; P J Brennan; T H Rea; R L Modlin
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

6.  Analysis of naturally occurring delayed-type hypersensitivity reactions in leprosy by in situ hybridization.

Authors:  C L Cooper; C Mueller; T A Sinchaisri; C Pirmez; J Chan; G Kaplan; S M Young; I L Weissman; B R Bloom; T H Rea; R L Modlin
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.